Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Novo Nordisk launches Wegovy pill in Germany as Eli Lilly readies rival — 1dNovo Nordisk is rolling out Wegovy as an oral weight‑loss pill in Germany, the EU’s first market to receive the formulation after EU approval, with prices expected around €170–€280 and strong competition from Eli Lilly’s Foundayo on the horizon. The launch leverages Wegovy’s dominant position in the oral obesity market, while analysts weigh the impact of the tablet on growth, pricing, and payer access across Europe.

Tom Gallagher Curious how many insurers in Germany will actually cover this at launch, oral obesity meds still feel like they're priced for a niche market.

Lilly's $2.9B deal adds treatments for Graves' disease and food allergies — 2dEli Lilly is acquiring Merida Biosciences for about $2.88 billion in cash, expanding its immunology and allergic-disease pipeline beyond its obesity drugs, with the deal expected to close in Q4 2026 and marking Lilly’s ongoing aggressive M&A strategy. Merida’s lead program MER511 targets Graves’ disease and thyroid eye disease, while MER769 is in preclinical development for food allergy, asthma and chronic spontaneous urticaria, underscoring a broadened portfolio as Lilly references roughly $29 billion in upfront and milestone payments this year across acquisitions.

China's Novo Nordisk Oral Wegovy Filing AcceptedBusiness — Aug 27, 2026Novo Nordisk trades near its average price target as China regulators accept the oral Wegovy application, underscoring a regulatory catalyst amid strong GLP-1 growth potential. The China market is heating up with Eli Lilly and others racing to offer pill-based options, and analysts project GLP-1 sales in China to surge to around 30 billion yuan in the next five to seven years, driving competition and market leadership shifts.

Video — YouTubeVERDICT WATCH: MA v. Lindsay Clancy - Day 26 | Accused Killer Mom TrialCOURT TV · 1.7M views · Sep 2, 2026

Novo Nordisk Tests Lower Wegovy Doses — Aug 19, 2026Novo Nordisk is conducting a late-stage study to identify the lowest effective dose of Wegovy, testing two low doses against placebo in 450 participants as it seeks to preserve its share in a obesity drug market projected to exceed $100 billion annually by 2030. The trial, which began on August 12 and runs through 2028, follows competitive pressure from Eli Lilly and comes after Wegovy's recent sales performance, with dose strengths undisclosed.

IJRDem Senate Hopeful Backed Trans Prison Policy — Female Inmate Says Convicted Killer Threatened To Rape HerNicole Silverio · 4 min · 9h

Rice Partnership Raises Eli Lilly Stake to 20,667 Shares, 2.6% of PortfolioBusiness — Jul 21, 2026Rice Partnership LLC increased its Eli Lilly stake to 20,667 shares (~$19.0 million) and opened a new 7,783-share position in Cheniere Energy, while trimming its iShares MSCI Germany ETF holding to 618,221 shares (~$24.5 million) and adding a 31,967-share position in JPMorgan Municipal ETF (~$1.6 million) in the first quarter.

RankingMost underrated cities in AmericaAmerica's biggest cities hog all the spotlight, while dozens of smaller gems get overlooked despite great food, culture, and character. These underrated cities deserve recognition beyond the usual coastal favorites. Cast your vote and help crown the most underappreciated city in the country.693 votes · 21 candidates

Lilly Retatrutide Meets Endpoints in Phase 3 Trials — Jul 23, 2026Eli Lilly announced positive Phase 3 results for retatrutide in TRIUMPH-2 and TRIUMPH-3, showing substantial weight loss and improved metabolic and cardiovascular risk markers, with average losses ranging roughly from the high 20s to the mid-50s pounds across different doses. The company plans to submit a Biologics License Application to the FDA in early 2027 as it moves toward global regulatory submissions for obesity and related conditions.

UK Approves Foundayo Oral GLP-1 Pill; NHS Decision Pending — Aug 10, 2026The UK has become the first European nation to approve Eli Lilly’s Orforglipron, sold as Foundayo, a once-daily GLP-1 pill for weight management and type 2 diabetes with specific BMI criteria and a multi-dose ramp-up. The MHRA emphasized prescription-only status and ongoing safety reviews, with NHS access still under consideration by NICE and not yet widely available.

Trump Announces $250 Weight Loss Drugs In Latest ‘TrumpRx’ Deal — Nov 6, 2025President Donald Trump unveiled steep discounts on GLP-1 weight loss drugs in deals with pharmaceutical giants Eli Lilly and Novo Nordisk in a Thursday Oval Office announcement. The obesity drugs Zepbound, marketed by…

Insurers, Medical Stocks Rally Ahead of EarningsBusiness — Jul 20, 2026From penny-stock hopefuls like Vizsla Silver and Clover Health to heavyweight medical names such as Danaher, Intuitive Surgical and Eli Lilly, investors are weighing high-growth potential against execution risk as volumes, profitability, and catalysts drive attention. Insurance stocks Cincinnati Financial, Reinsurance Group of America, Oscar Health, Willis Towers Watson and Aflac are poised to outperform, while Custom Health Holdings’ bid for Evergreen Pharmacy and Alnylam Pharmaceuticals’ RNAi-focused pipeline illustrate ongoing deal activity and biotech risk-reward in a rate-sensitive, geopolitically unsettled market.

On X · @HommebTHThai Actor-Model Wave Thanapat Appears for MMAM at Seoul Fashion Week SS27The post by @HommebTH shares a video announcing Wave’s presence in the MMAM Spring/Summer 2027 show at Seoul Fashion Week, generating strong positive engagement within Thai entertainment and BL/fashion communities. Reactions consist of near-uniform excitement, compliments, and hype with no meaningful opposing cluster.1,250 likes · now